Atossa reports FY2023 results: $88.5M cash, R&D spend up; two Phase 2 trials fully enrolled

ATOSSA THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.05

Ended FY2023 with $88.5M cash and equivalents, no debt.
Total operating expenses were $31.4M, up from $27.7M in FY2022, driven by higher R&D and G&A.
Two Phase 2 trials fully enrolled (Karisma-Endoxifen and I-SPY2); top-line data awaited H2 2024.
Recorded $3.0M impairment charge on investment in DCT; interest income rose to $4.3M from $0.9M.
Data from EVANGELINE Phase 2 study to be presented at AACR Annual Meeting on April 9, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ATOSSA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-039634

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.